Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

OSRH

OSR Holdings Inc

Nov 24 • 04:00PM ET

0.6497

+0.0871 15.48 %

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.00	Insider Own	60.64%	Shs Outstand	23.67M	Perf Week	33.90%
Market Cap	16.68M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.11M	Perf Month	7.64%
Enterprise Value	71.09M	PEG	-	EPS next Q	-0.12	Inst Own	0.88%	Short Float	7.49%	Perf Quarter	-33.58%
Income	-15.21M	P/S	6.62	EPS this Y	-	Inst Trans	16.28%	Short Ratio	0.10	Perf Half Y	-42.50%
Sales	2.52M	P/B	0.19	EPS next Y	-	ROA	-15.35%	Short Interest	0.76M	Perf YTD	-94.37%
Book/sh	3.46	P/C	7.65	EPS next 5Y	-	ROE	-31.41%	52W High	12.54 -94.82%	Perf Year	-94.03%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	-1003.77% -265.93%	ROIC	-18.56%	52W Low	0.45 43.42%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-259.39%	Volatility	17.61% 12.99%	Perf 5Y	-
Dividend TTM	-	EV/Sales	28.21	EPS Y/Y TTM	-1763.56%	Oper. Margin	-558.30%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.20	Sales Y/Y TTM	-	Profit Margin	-602.49%	RSI (14)	55.67	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.21	EPS Q/Q	-74.83%	SMA20	9.60%	Beta	1.47	Target Price	10.00
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	6.08%	Rel Volume	3.70	Prev Close	0.56
Employees	5	LT Debt/Eq	0.00	Earnings	Sep 03	SMA200	-51.84%	Avg Volume	7.87M	Price	0.65
IPO	Mar 17, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	29,120,939	Change	15.48%

Nov-21-25 09:20AM	Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones (PR Newswire) +23.38%
Nov-14-25 11:10AM	OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion (PR Newswire) -8.83%
Nov-06-25 08:30AM	OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study (PR Newswire) +13.98%
Oct-20-25 11:40AM	Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target (Newsfile) +25.67%
Oct-14-25 08:30AM	OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care (PR Newswire)
05:30PM	Loading…
Sep-09-25 05:30PM	OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity (PR Newswire) +9.58%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +96.12%
Aug-01-25 01:29PM	OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025 (PR Newswire) -6.67%
Jul-31-25 12:45PM	OSR Holdings Provides Transparency Update on Equity Financing Instruments (PR Newswire) -20.44%
Jul-30-25 04:10PM	OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure (PR Newswire) -6.99%
Jul-28-25 05:49AM	OSR Holdings to acquire South Koreas medical device company Woori IO (Medical Device Network)
Jul-24-25 07:30AM	OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology (PR Newswire) -5.88%
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire) -7.02%
Jul-08-25 10:03AM	OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG (PR Newswire)
May-22-25 07:36AM	OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token (PR Newswire) +5.25%
07:30AM	Loading…
May-02-25 07:30AM	Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics (PR Newswire)
Apr-09-25 07:54AM	Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology (PR Newswire)
Apr-03-25 07:30AM	OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies (PR Newswire) +68.03%
Mar-26-25 07:16AM	Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma (PR Newswire) +136.87%
Mar-25-25 07:00AM	OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer (PR Newswire) -7.51%

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

OSRH

OSR Holdings Inc

Upgrade your FINVIZ experience